Brent Pfeiffenberger - 19 May 2026 Form 4 Insider Report for Corbus Pharmaceuticals Holdings, Inc. (CRBP)

Reporting relationship: Director
Issuer ticker: CRBP
Reported as of: 19 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 21 May 2026, 17:04:18 UTC
Prior SEC filing: 19 May 2026
Next SEC filing: 09 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/Meghan Houghton, Attorney-in-Fact for Brent Pfeiffenberger

Key filing fact

Brent Pfeiffenberger filed Form 4 for Corbus Pharmaceuticals Holdings, Inc. (CRBP) on 21 May 2026.

Key facts

This page summarizes Brent Pfeiffenberger's Form 4 filing for Corbus Pharmaceuticals Holdings, Inc. (CRBP).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 21 May 2026, 17:04.

Change

Previous filing in this sequence was filed on 19 May 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002001162 Primary reporting owner

Pfeiffenberger Brent

Relationship: Director
Address: C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 500 RIVER RIDGE DRIVE, NORWOOD
Signature: /s/Meghan Houghton, Attorney-in-Fact for Brent Pfeiffenberger
Signature date: 21 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CRBP transaction

Common Stock, par value $0.0001 per share

Award

Transaction value
Shares: +7,500
Change %
Price: $0.000000^*
Shares after: 7,500
Date: 19 May 2026
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CRBP transaction Derivative

Stock options (right to buy)

Award

Transaction value
Shares: +24,700
Change %
Price: $0.000000^*
Shares after: 24,700
Date: 19 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 24,700
Exercise price: $9.15
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

On May 19, 2026, 7,500 restricted stock units ("RSUs") were granted, which will be settled in shares of common stock, par value $0.0001. The RSUs will vest in three equal annual installments on each of the first three anniversaries of the grant date, subject to continued service to the Company through each applicable vesting date.

Footnote F2

This amount includes 7,500 unvested RSUs that were granted on May 19, 2026 and will vest in three equal annual installments on each of the first three anniversaries of the grant date, subject to continued service to the Company through each applicable vesting date.

Footnote F3

The option award was made in accordance with the terms of the issuer's 2024 Equity Compensation Plan. The option will vest in three equal annual installments on each of the first three anniversaries of the grant date, subject to continued service to the Company through each applicable vesting date.